In pursuit of our mission, advancing tomorrow's discoveries, Advanced Cancer Therapeutics has obtained exclusive licenses to two novel anti-cancer small molecule compounds as well as a pharmaceutical vaccine for human papillomavirus (HPV) derived from tobacco plants. The pipeline below depicts these three products selected from several opportunities discovered by scientists at the James Graham Brown Cancer Center in Louisville.

prioritized anti-cancer product pipeline

High glucose consumption is common in cancer cells versus normal cells. 3PO is a novel small molecule which has already demonstrated anti-cancer effects in five (5) different animal cancer models. Involving both hematological (blood cancers) and solid tumors, there have been no noticeable toxic affects to these animals at low and high doses. 3PO's novel mechanism of action blocks the uptake of glucose in cancer cells, starving cancer cells of an important source of energy needed for growth and disease progression.

As a key molecular target in oncology, ACT is developing a series of next generation small molecule compounds through its medicinal chemistry efforts.

4-IPP is a novel small molecule compound which is initially targeted for development in oncology, with subsequent evaluation of its potential to address various unmet medical needs in autoimmune related diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis. As it relates to oncology, macrophage migration inhibitory factor (MIF) promotes multiple pro-angiogenic growth factors (VEGF and IL-8) and contributes to tumor cell division, metastases and tumor vascularization (i.e., angiogenesis). Compound 4-IPP exhibits anti-tumor activity by blocking tumor-specific angiogenesis, with no observed toxicities, in several animal cancer studies. We believe 4-IPP could serve as front-line therapy against bulk tumors and reduce the risk of recurrence of primary tumors or eventual metastasis.

As a key molecular target in oncology, ACT is developing a series of next generation small molecule compounds through its medicinal chemistry efforts.

Human Papillomavirus (HPV) is a leading cause of cervical cancer and approximately 20 million people are currently infected with this sexually transmitted disease (STD). According to the Centers For Disease Control and Prevention, at least 80 percent of women will have acquired genital HPV infection by age 50 with about 6.2 million Americans contracting a new genital HPV infection each year. The U.S. FDA recently approved the first HPV cervical cancer vaccine that includes a portion of the L1 capsid protein (Gardasil by Merck & Co.) to guard against this terrible disease. Advanced Cancer Therapeutics is developing a novel HPV vaccine which targets the L2 capsid protein that we believe should provide broader immune protection to patients at risk of contracting cervical cancer. ACT intends to manufacture its novel HPV vaccine from tobacco mosaic plants, promising to be very cost effective for people at risk of contracting HPV in both developed and developing nations.